

**Subject:** Manuscript submitted to Dove Medical Press  
**From:** Editor-in-Chief <editor-in-Chief@dovepress.com>  
**Date:** Wed, 15 Dec 2010 17:11:29 +0000 (UTC)  
**To:** harri.hemila@helsinki.fi

Dear Dr Hemila,

The peer review report on your submission is below, which identifies some points to be addressed. Consequently, and provided that these points are satisfactorily addressed, we would be happy to consider your manuscript for publication.

Please Note: We need you to respond to this email to confirm that you wish to proceed and intend to submit a revised manuscript within 21 days. If you require more time to revise and resubmit please advise us and we will try to accommodate you.

=====  
Submit your revised manuscript here:  
[http://www.dovepress.com/upload\\_files\\_new.php?submission\\_id=16567&l=49tzfu7H0yGifBlMcIWdUHY074333](http://www.dovepress.com/upload_files_new.php?submission_id=16567&l=49tzfu7H0yGifBlMcIWdUHY074333)

When you submit your revised manuscript please provide a summary of your responses to the peer reviewers' comments.

=====  
If you have any questions please email them to me at [ed@dovepress.com](mailto:ed@dovepress.com)

SUBMISSION DATA:  
Title: Zinc Lozenges May Shorten the Duration of Colds: a Systematic Review  
Journal: Clinical Pharmacology: Advances and Applications  
Submission ID: 16567

OUR COMMENTS (IF ANY):

REVIEWER 1 EVALUATION

The Manuscript (Submission ID: 16567) entitled "Zinc Lozenges May Shorten the Duration of Colds: a Systematic Review" reviewed the possible effects of Zinc Lozenge on common cold. This lengthy article does not give the significant novel information about the Zinc Lozenge in cold symptoms. More over, the article required to be shorten for the easy understanding of the broad authorship. Also it would be appropriate to remove the most of tables and figures. Hence, the manuscript lacks novelty and does not significantly contribute to the knowledge of the existing literature. All these aspects make this paper very weak and unacceptable for publication.

REVIEWER 2 EVALUATION

This manuscript provides important information to the potential efficacy and tolerability of a natural multi-herbal formula (Immumax) in the treatment of patients suffering from common cold.

Minor comments:

Sixty-two patients were randomized to either Immumax or placebo treatment groups in this study. But Table 1 showed that there were 11 male patients and 39 female patients in placebo group and 13 male patients and 37 female patients in Immumax group. It seems that the number of patients of Tables 1 is wrong.

Yours sincerely

Professor Arthur E. Frankel  
Editor-in-Chief  
Clinical Pharmacology: Advances and Applications  
Dove Medical Press  
[www.dovepress.com](http://www.dovepress.com) - open access to scientific and medical research